万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://ard.bmj.com/
3、投稿网址：https://mc.manuscriptcentral.com/ard
4、官网邮箱：ard@bmj.com
5、官网电话：+44 (0)207 387 4410
6、期刊刊期：月刊，一年出版12期。
2021年8月3日星期二
投稿须知【官网信息】
For authors
Editorial policy
Annals of the Rheumatic Diseases adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. To view all BMJ Journal policies please refer to the BMJ Author Hub policies page.
Plan S compliance
Annals of the Rheumatic Diseases is a Plan S compliant Transformative Journal. Transformative Journals are one of the compliance routes offered by cOAlition S funders, such as Wellcome, WHO and UKRI. Find out more about Transformative Journals and Plan S compliance on our Author Hub.
Copyright and authors’ rights
Articles are published under an exclusive licence or non-exclusive licence for UK Crown employees or where BMJ has agreed CC BY applies. For US Federal Government officers or employees acting as part of their official duties, the terms are as stated in accordance with our licence terms. Authors or their employers retain copyright. Open access articles can be reused under the terms of the relevant Creative Commons licence to facilitate reuse of the content; please refer to the Annals of the Rheumatic Diseases Author Licence for the applicable Creative Commons licences”.
When publishing in Annals of the Rheumatic Diseases, authors choose between three licence types – exclusive licence granted to BMJ, CC-BY-NC and CC-BY (Creative Commons open access licences require payment of an article processing charge). As an author you may wish to post your article in an institutional or subject repository, or on a scientific social sharing network. You may also link your published article to your preprint (if applicable). What you can do with your article, without seeking permission, depends on the licence you have chosen and the version of your article. Please refer to the BMJ author self archiving and permissions policies page for more information.
More information on copyright and authors’ rights.
Preprints
Preprints foster openness, accessibility and collaboration by allowing authors to make their findings immediately available to the research community and receive feedback on an article before it is submitted to a journal for formal publication.
BMJ fully supports and encourages the archiving of preprints in any recognised, not-for-profit server such as medRxiv. BMJ does not consider the posting of an article in a dedicated preprint repository to be prior publication.
Preprints are reports of work that have not been peer-reviewed; Preprints should therefore not be used to guide clinical practice, health-related behaviour or health policy. For more information, please refer to our Preprint policy page.
Article transfer service
BMJ is committed to ensuring that all good quality research is published. Our article transfer service helps authors find the best journal for their research while providing an easy and smooth publication process. If authors agree to transfer their manuscript, all versions, supplementary files and peer reviewer comments are automatically transferred; without the need to resubmit or reformat.
Authors who submit to the Annals of the Rheumatic Diseases and are rejected will be offered the option of transferring to RMD Open or Lupus Science & Medicine. If your transferred article is accepted for publication by one of these journals, you will receive a 20% discount on the article processing charge.
RMD Open is an official journal of EULAR and the open access companion journal to the Annals of the Rheumatic Diseases. It is indexed by Science Citation Index Expanded, Current Contents/Clinical Medicine, MEDLINE, PubMed Central, Scopus, Embase (Excerpta Medica), DOAJ, and Google Scholar, and covers musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Find out more about RMD Open.
Lupus Science & Medicine is the official journal of the Lupus Foundation of America. It is indexed by Science Citation Index Expanded, Current Contents/Clinical Medicine, MEDLINE, PubMed Central, Scopus, Embase (Excerpta Medica), DOAJ, and Google Scholar, and covers all aspects of lupus and related diseases. Find out more about Lupus Science & Medicine.
Please note that the article transfer service does not guarantee acceptance but you should receive a quicker initial decision on your manuscript.
Contact the Product Owner of BMJ’s Article Transfer Service for more information or assistance.
ORCID
Annals of the Rheumatic Diseases mandates ORCID iDs for the submitting author at the time of article submission; co-authors and reviewers are strongly encouraged to also connect their ScholarOne accounts to ORCID. We strongly believe that the increased use and integration of ORCID iDs will be beneficial for the whole research community.
Please find more information about ORCID and BMJ’s policy on our Author Hub.
Competing interests
All authors must download and complete a copy of the ICMJE Conflict of Interest disclosure form and send a copy to the corresponding author. The corresponding author will be required to upload these forms with the manuscript. A summary Competing Interests statement for all authors should also be included in the manuscript itself, which will appear in the published article. If there are no competing interests for any authors, the default statement on the published article will be ‘None declared’.
Data sharing
Annals of the Rheumatic Diseases adheres to BMJ’s Tier 3 data policy. We strongly encourage that data generated by your research that supports your article be made available as soon as possible, wherever legally and ethically possible. All research articles must contain a Data Availability Statement. For more information and FAQs, please see BMJ’s full Data Sharing Policy page.
Reporting patient and public involvement in research
BMJ encourages active patient and public involvement in clinical research as part of its patient and public partnership strategy. To support co-production of research we request that authors provide a Patient and Public Involvement statement in the methods section of their papers, under the subheading ‘Patient and public involvement’.
We appreciate that patient and public involvement is relatively new and may not be feasible or appropriate for all papers. However, the papers where it must be included are extended reports and concise reports. We therefore continue to consider papers where patients were not involved.
The Patient and Public Involvement statement should provide a brief response to the following questions, tailored as appropriate for the study design reported (please find example statements here):
At what stage in the research process were patients/the public first involved in the research and how?
How were the research question(s) and outcome measures developed and informed by their priorities, experience, and preferences?
How were patients/the public involved in the design of this study?
How were they involved in the recruitment to and conduct of the study?
Were they asked to assess the burden of the intervention and time required to participate in the research?
How were (or will) they be involved in your plans to disseminate the study results to participants and relevant wider patient communities (e.g. by choosing what information/results to share, when, and in what format)?
If patients were not involved please state this.
In addition to considering the points above we advise authors to look at guidance for best reporting of patient and public involvement as set out in the GRIPP2 reporting checklist.
If the Patient and Public Involvement statement is missing in the submitted manuscript we will request that authors provide it.
Clinical trials, including extension studies
Manuscripts on clinical trials are an important source of information and innovation in the therapeutic arena. Therefore it is necessary to report the respective data in a transparent way to allow readers optimal interpretation of the results and systematic reviews or meta-analyses to be done more easily. To this end, EULAR (partly in collaboration with ACR), has provided a number of frameworks, most importantly for reporting on clinical trials as well as extension studies.
These frameworks should guide authors in the preparation of their manuscript and should be regarded as a minimum set of data that need to be reported in the main body of the manuscript or supplementary material. ‘Minimum set’ means that additional data can be reported, provided that the core elements are included. Further, authors should abstain from forcing readers to guess data; in this respect, figures with data points should always include the actual data, either adjacent to the respective data point or in a small table within or beneath the figure, or in supplementary material. In this context, other EULAR or ACR-EULAR criteria and definitions should be considered, such as the RA classification criteria.
The protocol for the clinical trial must either be uploaded as a supplementary file for reviewers or a link to the published protocol should be included in the manuscript.
See also BMJ’s policies on trial registration.
Previously presented work
Manuscripts reporting on work previously presented at a conference or meeting should include an acknowledgement of prior presentation and full references to any published conference abstracts. Permission for republication of the abstract may be required from the copyright owner, if copyright in the work has been transferred to a third party.
Statistical analysis
Describe statistical methods with enough detail to enable the reader to judge its appropriateness for the study and to verify the reported results.
When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values.
Distinguish prespecified from exploratory analyses, including subgroup analyses.
Extra resource: For further information on common statistical errors to avoid, please read the article published by ARD’s Statistical Advisor, Stian Lydersen.
Tables and graphs
Tables and graphs are extremely important elements in scientific communication. Specific guidelines are below.
Extra resources: For further information, please read the articles on tables and graphs by ARD’s Graphical Advisor, Professor Maarten Boers, and view the accompanying video series.
Graphs
Consider if the data or message being presented is best conveyed to the reader in a graph rather than in any other form
Ensure that the message is easy to visualise and understand, and kept in context
Avoid graphical forms that distort the data or are prone to misinterpretation
Choose your graph type carefully for best visual clarity, and avoid chart ‘art’
Ensure data symbols and lines can be easily distinguished i.e. more prominent than axis lines, use solid greyscale or colour lines rather than pixellated/dashed lines
Data points on line graphs or data columns on bar charts should always include the actual data, ideally either adjacent to the respective data point or in a small table within or beneath the figure (if this is not feasible, the data can be included in supplementary material with a reference to this in the figure legend)
In bar or column graphs or boxplots, use solid greyscale or colour fills rather than patterned fills
Avoid non-essential grids, background shading, explanatory text and legends inside the graph
Keep axis titles and labels brief
Aim to fill the frame to avoid large areas of white space
Tables
Consider if the data or message being presented is best conveyed to the reader in a table rather than in any other form
Ensure that the data are easy to read and understand, and kept in context
Use categories and sub-categories effectively to highlight patterns in the data
Keep table titles, labels and footnotes brief
Avoid excessive precision in scaling in order to avoid cluttering the table
Video abstracts
We welcome video abstracts to accompany accepted research articles. These allow authors to personally talk through their work beyond the restrictions of a formal article to improve the user’s understanding. Note that we will not ask you to consider submitting a video abstract until your paper has been accepted. Please do not try to upload a video abstract upon initial submission of your manuscript.
……
更多详情：
https://ard.bmj.com/pages/authors/
